Get the Stockscreener App
455.45
1.00%
-4.61
Vertex Pharmaceuticals Inc stock is traded at $455.45, with a volume of 1.02M.
It is down -1.00% in the last 24 hours and up +5.43% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$460.06
Open:
$455.39
24h Volume:
1.02M
Relative Volume:
0.61
Market Cap:
$115.69B
Revenue:
$11.10B
Net Income/Loss:
$-988.90M
P/E Ratio:
-116.19
EPS:
-3.92
Net Cash Flow:
$-1.26B
1W Performance:
+1.10%
1M Performance:
+5.43%
6M Performance:
-1.79%
1Y Performance:
-4.92%
1-Day Range:
$454.00
$460.10
1-Week Range:
$441.92
$460.33
52-Week Range:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Redhawk Wealth Advisors Inc. Cuts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Compagnie Lombard Odier SCmA Raises Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Simon Quick Advisors LLC Increases Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
SG Americas Securities LLC Purchases 17,502 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Greenwood Capital Associates LLC Sells 6,572 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Stanley Laman Group Ltd. Buys New Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
UMB Bank n.a. Sells 1,666 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Yousif Capital Management LLC Lowers Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Moves -1.00%: What You Should Know - Nasdaq
Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Opinicus Capital Inc. Takes $397,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
CCM Investment Advisers LLC Grows Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Everhart Financial Group Inc. Has $1.07 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by RMR Wealth Builders - MarketBeat
806 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Ferguson Wellman Capital Management Inc. - MarketBeat
Integrated Advisors Network LLC Decreases Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Healey boosts life sciences tax incentives as 33 companies plan major expansions - The Business Journals
Boston drug company laying off 125 employees in R.I. - Boston.com
Boston probes misconduct claims against city official - Axios
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
Vertex Presents New Data on the Benefits of ALYFTREK - Insider Monkey
Vertex Pharmaceuticals lays off 125 workers in RI - WPRI.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Lifted by Wedmont Private Capital - MarketBeat
Boston drugmaker Vertex slashes Providence workforce, shrinks real estate following trial failure - The Business Journals
SeaCrest Wealth Management LLC Purchases New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex to lay off 125 employees in R.I., consolidate offices - The Boston Globe
Vertex lays off 125 staffers, slims Rhode Island campus after ditching failed diabetes cell-device combo - Fierce Biotech
Vertex lays off 125 staffers after halting work on diabetes 'cells plus device' therapy - FirstWord Pharma
After axing diabetes asset, Vertex lays off 140 staff - PharmaLive
After Axing Diabetes Asset, Vertex Lays Off 140 Staff - BioSpace
Five things: The Newbury GM, Zoominfo cuts, Vertex, Boston Scientific and casino night - The Business Journals
How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks? - MSN
Vertex lays off 125 workers after type 1 diabetes cell therapy failed study in March - Endpoints News
Vertex at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK
Vertex Pharmaceuticals Exec Says Cystic Fibrosis Portfolio Has About 9% Exposure To Medicare And About 23% Exposure To MedicaidGoldman Sachs Conference - marketscreener.com
Milestone reached on yet another Seaport building for Vertex - The Business Journals
Vertex Pharmaceuticals to lay off 125 Rhode Island workers. What we know. - Yahoo
Vertex Pharmaceuticals to lay off 125 R.I. employees - Providence Business News
$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga
2 Stocks to Buy if You're Worried About a Recession - AOL.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Increased by Procyon Advisors LLC - MarketBeat
Vertex presents promising new data from cystic fibrosis trials - Pharmafile
How Is Vertex Pharmaceuticals’ Stock Performance Compared To Other Biotech Stocks? - Barchart.com
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - MSN
Vertex Pharmaceuticals (NasdaqGS:VRTX) Highlights Clinical Benefits Of ALYFTREK At Cystic Fibrosis Conference - Yahoo Finance
Vertex presents new data on benefits of Alyftrek - The Pharma Letter
VRTX: Vertex Pharmaceuticals Reports Positive Outcomes from CFTR Modulator Studies | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals presents new data on ALYFTREK at ECFS Conference - TipRanks
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference | VRTX Stock News - GuruFocus
and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference - Business Wire
Vertex Pharmaceuticals discovers new PKD1 correctors - BioWorld MedTech
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):